Mean laboratory findings | Baseline | 1 month post-TACE | Significant change? (p values at 95% CI) |
---|---|---|---|
Haemoglobin | 12.36±1.66 | 12.31±1.73 | No (p=0.16) |
Platelet count | 147.7±64.85×103/L | 137.86±67.46×103/L | No (p=0.06) |
INR | 1.17±0.13 | 1.28±0.26 | Yes (p=0.008) |
Serum total bilirubin | 1.09±0.46 | 1.63±1.01 | Yes (p<0.001) |
Serum albumin | 3.54±0.45 | 3.1±0.56 | Yes (p<0.001) |
AST | 71±33 | 85±42 | Yes (p<0.001) |
ALT | 57±27 | 67±29 | Yes (p<0.001) |
AFP | 1056.79±2057.59 | 794.53±1578.62 | Yes (p<0.001) |
Blood urea | 31.27±7.58 | 30.73±6.59 | No (p=0.19) |
Serum creatinine | 0.81±0.19 | 0.83±0.22 | No (p=0.32) |
Sodium | 136.97±4.01 | 136.81±3.75 | No (p=0.70) |
Potassium | 4.2±0.49 | 4.13±0.51 | No (p=0.19) |
Clinical manifestations | Total patients | Group 1 patients | Group 2 patients |
Haematemesis | 10 (9.8%) | 1 of 48 pts (2.1%) | 9 of 54 pts (16.7%) |
Hepatic encephalopathy | 9 (8.8%) | None | 9 of 54 pts (16.7%) |
Ascites | 25 (24.5%) | None | 25 of 54 pts (46.3%) |
Child-Pugh score | Baseline | 1 month post-TACE | |
A | 102 pts (100%) | 60 pts (58.8%) | |
A5 | 50 pts (49%) | ||
Grp 1: 28 pts | |||
(58.3%) | |||
Grp 2: 23 pts | |||
A6 | (42.5%) | ||
52 pts (51%) | |||
Grp 1: 20 pts | |||
B | (41.6%) | 31 pts (30.4%) | |
C | Grp 2: 31 pts | 11 pts (10.8%) | |
(57.4%) | |||
None | |||
None |
Group 1 consists of patients with no points added to the Child-Pugh score 1 month after TACE. Group 2 consists of patients with one or more points added to the Child-Pugh score 1 month after TACE.
AFP, α-fetoprotein; ALT, alanine transaminase; AST, aspartate aminotransferase; Grp 1, Group 1; Grp 2, Group 2; Pts, patients; INR, international normalised ratio, TACE, transarterial chemoembolisation.